MET and lung carcinoma: c-Met alterations in lung cancer include gene mutation, amplification and protein overexpression.3,4 Recent studies reported a response rate of 40–70% in patients with MET exon 14 skipping mutation (MET ex14Δ).5–7 However, such MET alterations are only present in a rare subtype of NSCLC, accounting for only 3–4% of NSCLC cases.5,6 A much more limited response was observed in patients with MET amplification8–10 or c-Met overexpression.11,12 While c-Met overexpression occurs in approximately 20–25% of NSCLC patients,3,13,14 it has not yet been clearly defined as a clinically useful biomarker.